Melanocortin Receptor Activation

The melanocortin system comprises five G protein-coupled receptors (MC1R–MC5R) activated by peptides derived from pro-opiomelanocortin (POMC). Receptor subtype distribution across tissues determines whether activation produces pigmentation, appetite suppression, sexual arousal, immune modulation, or exocrine gland effects.

Overview

Pro-opiomelanocortin (POMC) is a large precursor protein synthesised primarily in the anterior pituitary gland, hypothalamic arcuate nucleus, and nucleus of the solitary tract, but also in the skin, immune cells, and testes. POMC undergoes cell-type-specific post-translational processing by prohormone convertases (PC1 and PC2), yielding a family of biologically active peptides with distinct tissue distributions. In the pituitary corticotrophs (cells of the anterior pituitary), POMC is primarily cleaved into ACTH and β-lipotropin. In the hypothalamus and skin, further processing by PC2 converts ACTH into α-MSH (alpha-melanocyte-stimulating hormone), β-MSH, and γ-MSH. These melanocortin peptides are the endogenous ligands for the five melanocortin receptors.

All five melanocortin receptors (MC1R–MC5R) are class A G protein-coupled receptors (GPCRs) that signal predominantly through Gαs protein coupling — activating adenylyl cyclase, elevating cyclic AMP (cAMP), and activating protein kinase A (PKA). Despite this shared intracellular signal transduction, the five receptors differ markedly in their tissue expression patterns, ligand affinities, and endogenous physiological roles. The therapeutic opportunity — and the pharmacological challenge — in melanocortin research is achieving receptor subtype selectivity: producing the desired effect (e.g. MC4R-mediated sexual arousal) while minimising off-target effects from other receptor subtypes (e.g. MC1R-mediated pigmentation, or MC2R-mediated adrenal stimulation).

How It Works

The five melanocortin receptors serve distinct physiological functions based on their tissue distribution. Understanding which receptor is activated by a given compound — and in which tissues that receptor is expressed — determines the expected biological effects.

MC1R — Skin Pigmentation (Melanogenesis)

MC1R is expressed primarily on melanocytes — the pigment-producing cells in the skin and hair follicles. Activation by α-MSH or synthetic agonists causes Gαs-mediated elevation of cAMP, which activates PKA. PKA phosphorylates the transcription factor CREB (cAMP response element-binding protein), which drives expression of MITF (microphthalmia-associated transcription factor) — the master regulator of melanocyte identity. MITF in turn activates the genes encoding the melanin-biosynthesis enzymes: tyrosinase (TYR), tyrosinase-related protein 1 (TYRP1), and DOPA-chrome tautomerase (DCT). These enzymes convert tyrosine through a series of oxidation steps to produce both eumelanin (brown/black) and phaeomelanin (red/yellow). In hair follicles, MC1R signalling also determines the ratio of eumelanin to phaeomelanin, influencing hair colour. Both PT-141 and Melanotan II activate MC1R, but at the doses used in sexual function research, PT-141's structural modifications shift its affinity toward MC4R, reducing its relative MC1R activity compared to Melanotan II.

MC2R — Adrenal Cortex and Cortisol Release

MC2R is the ACTH receptor — it binds only ACTH (not α-MSH or synthetic melanocortin peptides) and is expressed almost exclusively in the adrenal cortex. Activation drives glucocorticoid (cortisol) synthesis and secretion. PT-141 and Melanotan II have minimal affinity for MC2R (which requires the full ACTH sequence for binding), so adrenal stimulation is not a pharmacological concern for these research compounds. MC2R is relevant to understanding POMC biology but not to the pharmacology of synthetic melanocortin peptides currently in research use.

MC3R and MC4R — Central Appetite and Energy Homeostasis

MC3R and MC4R are expressed centrally in the hypothalamus and other limbic and brainstem structures involved in energy balance. In the hypothalamic arcuate nucleus, POMC neurons project to the paraventricular nucleus (PVN) and other downstream areas and release α-MSH, activating MC3R and MC4R. This activation suppresses appetite via inhibition of feeding circuits — reducing NPY/AgRP neuronal activity and promoting satiety. MC4R is particularly critical: loss-of-function MC4R mutations are the most common monogenic cause of severe human obesity, accounting for approximately 5% of early-onset severe obesity cases. MC4R activation also increases energy expenditure through sympathetic nervous system activation. These appetite-suppressing and energy-expenditure-increasing effects of melanocortin agonism are pharmacologically relevant: both PT-141 and Melanotan II produce appetite suppression in research contexts, which is an effect attributed to MC4R activation in the hypothalamus.

MC4R — Sexual Arousal Mechanism (PT-141 / Bremelanotide)

Sexual arousal mediated by the melanocortin system operates via MC4R (and potentially MC3R) expressed in limbic structures including the medial preoptic area (mPOA), paraventricular nucleus (PVN), and hippocampus. The precise neural circuit mechanism has been partially characterised in rodent models: MC4R activation in the PVN triggers the release of oxytocin, which descends to the lumbosacral spinal cord and activates the erectile or vasocongestion response through spinal nitric oxide mechanisms. In the mPOA — a region central to sexual motivation — MC4R activation increases dopamine release, which modulates sexual desire and motivation. This mechanism is fundamentally different from PDE5 inhibitors (sildenafil, tadalafil), which act peripherally on vascular smooth muscle. PT-141 acts centrally, engaging the neurological component of arousal — which is why research has investigated its potential utility in conditions where the psychological/motivational component of sexual dysfunction is prominent. The FDA-approved dose for HSDD in premenopausal women (Vyleesi, 1.75 mg subcutaneous) produces sexual arousal effects within 45 minutes, with duration of 8–12 hours.

MC5R — Exocrine Glands and Immune Modulation

MC5R is expressed broadly in exocrine glands (sebaceous, lacrimal, Harderian glands, and others) and in immune cells. Its physiological role in humans is less well characterised than MC1R or MC4R, but MC5R activation has been investigated in the context of sebum production (relevant to acne research), lacrimal gland function (dry eye), and immune regulation. α-MSH exerts anti-inflammatory effects through melanocortin receptors including MC5R on macrophages and other immune cells, reducing pro-inflammatory cytokine production. This anti-inflammatory property of the broader melanocortin system has been noted as potentially relevant to the therapeutic profile of melanocortin agonists used in research.

Peptides That Work Via This Mechanism

Compound	Primary Receptor Targets	Profile
PT-141 (Bremelanotide)	MC4R > MC3R (selective; FDA-approved for HSDD)	View profile
Melanotan II	MC1R, MC3R, MC4R, MC5R (non-selective)	View profile

PT-141's cyclic structure and amino acid modifications confer greater selectivity for MC4R over MC1R compared to Melanotan II, producing less pronounced tanning at doses used for sexual function research. Melanotan II's broader receptor activation profile produces simultaneous pigmentation and arousal effects.

Research Context

The melanocortin system's role in energy homeostasis was established through the discovery of the agouti gene in mice in the early 1990s. Agouti is an endogenous antagonist at MC1R and MC4R: mice overexpressing agouti (the "yellow obese mouse") develop profound obesity, yellow fur, and increased susceptibility to diabetes — all attributable to inappropriate MC4R and MC1R blockade. The identification of MC4R loss-of-function mutations as the most common monogenic obesity gene in humans followed from this model, establishing MC4R as a validated obesity target. Setmelanotide, a selective MC4R agonist, was subsequently developed and approved for specific genetic obesity syndromes caused by POMC, PCSK1, or LEPR deficiency.

The sexual function research pathway developed separately. Early observations that melanotan (MT-I) and MT-II induced spontaneous erections in male volunteers during tanning trials led to the deliberate development of PT-141 as a sexual dysfunction agent. PT-141 (later named bremelanotide) was evaluated in Phase 3 trials and received FDA approval in 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women — the first centrally-acting pharmacological treatment approved for female sexual dysfunction. Its mechanism via CNS melanocortin receptors distinguishes it from the PDE5 inhibitor class (sildenafil, tadalafil), which work peripherally on vascular smooth muscle and are primarily approved for male erectile dysfunction. Research continues into melanocortin agonism for male sexual dysfunction, where the central mechanism may offer advantages in psychogenic or neurogenic erectile dysfunction that does not respond to peripheral vascular agents.

Related Mechanisms

GLP-1 Receptor Agonism

Another central appetite-regulating mechanism — GLP-1 and melanocortin pathways converge in hypothalamic satiety circuits.

→

Melanocortin Peptides — Class Overview

PT-141 and Melanotan II compared by receptor selectivity and research applications.

→

PT-141 vs Melanotan II — Comparison

MC4R-selective vs broad melanocortin agonism — dose, selectivity, and research applications.

→